西妥昔-话题@MedSci

#西妥昔#

72篇内容 | 2308人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1679438, encodeId=0c9816e94384a, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JAMA Surg：接受贝伐单抗或西妥昔单抗治疗的转移性结直肠癌患者原发肿瘤部位与死亡风险, objectType=article, longId=113813, objectId=ea2a11381327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea2a11381327, replyNumber=0, likeNumber=71, createdTime=2018-02-08, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea2a11381327, moduleTitle=JAMA Surg：接受贝伐单抗或西妥昔单抗治疗的转移性结直肠癌患者原发肿瘤部位与死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea2a11381327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679439, encodeId=0aa416e94397b, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Oncol:西妥昔单抗在晚期NSCLC中是否有一席之地？, objectType=article, longId=122066, objectId=7a42122066cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a42122066cd, replyNumber=0, likeNumber=71, createdTime=2018-04-09, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a42122066cd, moduleTitle=Lancet Oncol:西妥昔单抗在晚期NSCLC中是否有一席之地？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a42122066cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679431, encodeId=ea8916e94311c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JAMA Oncology：头颈部鳞状细胞癌KRAS变异与西妥昔单抗反应, objectType=article, longId=98232, objectId=5bb1982322d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bb1982322d, replyNumber=0, likeNumber=89, createdTime=2017-06-07, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bb1982322d, moduleTitle=JAMA Oncology：头颈部鳞状细胞癌KRAS变异与西妥昔单抗反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bb1982322d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679440, encodeId=5b3d16e94408a, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=EUR J CANCER：紫杉醇、西妥昔单抗和放疗的联合治疗能够控制汗孔癌, objectType=article, longId=124077, objectId=968d1240e711, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968d1240e711, replyNumber=0, likeNumber=69, createdTime=2018-05-15, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968d1240e711, moduleTitle=EUR J CANCER：紫杉醇、西妥昔单抗和放疗的联合治疗能够控制汗孔癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968d1240e711)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679434, encodeId=877c16e9434b0, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JAMA Oncol：西妥昔单抗对接受紫杉醇、顺铂及放疗的食管癌患者的影响, objectType=article, longId=104919, objectId=1a521049193b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a521049193b, replyNumber=0, likeNumber=63, createdTime=2018-04-23, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a521049193b, moduleTitle=JAMA Oncol：西妥昔单抗对接受紫杉醇、顺铂及放疗的食管癌患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a521049193b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679433, encodeId=593c16e943379, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=CLIN CANCER RES：Motolimod联合西妥昔单抗治疗复发或转移性头颈部鳞状细胞癌, objectType=article, longId=99868, objectId=a6ba99868a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6ba99868a9, replyNumber=0, likeNumber=128, createdTime=2018-04-18, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6ba99868a9, moduleTitle=CLIN CANCER RES：Motolimod联合西妥昔单抗治疗复发或转移性头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6ba99868a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679437, encodeId=9efb16e943745, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤, objectType=article, longId=113721, objectId=8ede113e21b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ede113e21b9, replyNumber=0, likeNumber=95, createdTime=2018-03-02, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ede113e21b9, moduleTitle=CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ede113e21b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679432, encodeId=6dc416e9432c9, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JCO：西妥昔单抗联合放化疗治疗HIV相关肛管癌利弊皆有！, objectType=article, longId=99749, objectId=79f199e49ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79f199e49ce, replyNumber=0, likeNumber=59, createdTime=2018-05-06, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79f199e49ce, moduleTitle=JCO：西妥昔单抗联合放化疗治疗HIV相关肛管癌利弊皆有！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79f199e49ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679430, encodeId=7ab016e94304f, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JCO：西妥昔单抗联合放化疗治疗伴有HIV感染的肛门癌患者的效果有待商榷, objectType=article, longId=86555, objectId=b10c86555ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b10c86555ea, replyNumber=0, likeNumber=67, createdTime=2017-07-03, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b10c86555ea, moduleTitle=JCO：西妥昔单抗联合放化疗治疗伴有HIV感染的肛门癌患者的效果有待商榷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b10c86555ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679429, encodeId=4c7016e9429a0, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JCO：西妥昔单抗联合放化疗治疗伴有HIV感染的肛门癌患者的效果有待商榷, objectType=article, longId=84350, objectId=8a048435058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a048435058, replyNumber=0, likeNumber=99, createdTime=2017-01-09, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a048435058, moduleTitle=JCO：西妥昔单抗联合放化疗治疗伴有HIV感染的肛门癌患者的效果有待商榷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a048435058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679428, encodeId=4b6b16e9428ae, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3), objectType=article, longId=76991, objectId=b8c4e6991d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8c4e6991d8, replyNumber=0, likeNumber=47, createdTime=2017-08-20, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8c4e6991d8, moduleTitle=Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8c4e6991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679427, encodeId=b88316e9427f9, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, objectType=article, longId=56018, objectId=86745601843, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86745601843, replyNumber=0, likeNumber=69, createdTime=2016-01-29, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86745601843, moduleTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86745601843)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679423, encodeId=90e416e94230a, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Oncol：EGFR抗体西妥昔单抗可以作为结直肠癌维持治疗的优化方案（COIN-B研究）, objectType=article, longId=33906, objectId=840533906d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=840533906d2, replyNumber=0, likeNumber=96, createdTime=2014-07-15, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=840533906d2, moduleTitle=Lancet Oncol：EGFR抗体西妥昔单抗可以作为结直肠癌维持治疗的优化方案（COIN-B研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=840533906d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679420, encodeId=b6ea16e942071, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=GCS 2014：西妥昔单抗不改善食管癌患者生存, objectType=article, longId=29991, objectId=4d072999181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d072999181, replyNumber=0, likeNumber=84, createdTime=2014-02-05, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d072999181, moduleTitle=GCS 2014：西妥昔单抗不改善食管癌患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d072999181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679424, encodeId=61a116e942443, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, objectType=article, longId=33909, objectId=cae8339099f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cae8339099f, replyNumber=0, likeNumber=78, createdTime=2014-05-31, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cae8339099f, moduleTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cae8339099f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679419, encodeId=8b9616e9419ee, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Oncol：不推荐化疗+西妥昔单抗治疗晚期非小细胞肺癌, objectType=article, longId=27162, objectId=57e42e162e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57e42e162e8, replyNumber=0, likeNumber=62, createdTime=2014-02-23, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57e42e162e8, moduleTitle=Lancet Oncol：不推荐化疗+西妥昔单抗治疗晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57e42e162e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679426, encodeId=cb1d16e9426c6, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Cancer Chemother Pharmacol：西妥昔单抗安全用于肾损伤的癌症患者, objectType=article, longId=36452, objectId=29e336452b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29e336452b5, replyNumber=0, likeNumber=68, createdTime=2014-07-13, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29e336452b5, moduleTitle=Cancer Chemother Pharmacol：西妥昔单抗安全用于肾损伤的癌症患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29e336452b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679417, encodeId=4d2716e94174e, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=西妥昔单抗联合同步放化疗不改善NSCLC生存, objectType=article, longId=26278, objectId=201b262e84e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=201b262e84e, replyNumber=0, likeNumber=73, createdTime=2014-06-27, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=201b262e84e, moduleTitle=西妥昔单抗联合同步放化疗不改善NSCLC生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=201b262e84e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679425, encodeId=8e1e16e9425e7, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=ASCO 2014：贝伐单抗+化疗方案和西妥昔单抗+化疗方案一线治疗转移性结直肠癌患者的疗效的研究（CALGB/SWOG 80405研究）, objectType=article, longId=35755, objectId=885735e5522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=885735e5522, replyNumber=0, likeNumber=66, createdTime=2015-03-04, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=885735e5522, moduleTitle=ASCO 2014：贝伐单抗+化疗方案和西妥昔单抗+化疗方案一线治疗转移性结直肠癌患者的疗效的研究（CALGB/SWOG 80405研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=885735e5522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679422, encodeId=cd5b16e9422c4, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Oncol：FOLFOX方案加西妥昔单抗用于结直肠癌维持治疗方案（COIN-B研究）, objectType=article, longId=33905, objectId=599233905c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=599233905c3, replyNumber=0, likeNumber=76, createdTime=2014-05-02, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=599233905c3, moduleTitle=Lancet Oncol：FOLFOX方案加西妥昔单抗用于结直肠癌维持治疗方案（COIN-B研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=599233905c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

西妥昔

2020-05-29

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JAMA Surg：接受贝伐单抗或西妥昔单抗治疗的转移性结直肠癌患者原发肿瘤部位与死亡风险

2018-02-08

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Oncol:西妥昔单抗在晚期NSCLC中是否有一席之地？

2018-04-09

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JAMA Oncology：头颈部鳞状细胞癌KRAS变异与西妥昔单抗反应

2017-06-07

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

EUR J CANCER：紫杉醇、西妥昔单抗和放疗的联合治疗能够控制汗孔癌

2018-05-15

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JAMA Oncol：西妥昔单抗对接受紫杉醇、顺铂及放疗的食管癌患者的影响

2018-04-23

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

CLIN CANCER RES：Motolimod联合西妥昔单抗治疗复发或转移性头颈部鳞状细胞癌

2018-04-18

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤

2018-03-02

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JCO：西妥昔单抗联合放化疗治疗HIV相关肛管癌利弊皆有！

2018-05-06

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JCO：西妥昔单抗联合放化疗治疗伴有HIV感染的肛门癌患者的效果有待商榷

2017-07-03

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JCO：西妥昔单抗联合放化疗治疗伴有HIV感染的肛门癌患者的效果有待商榷

2017-01-09

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3)

2017-08-20

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验

2016-01-29

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Oncol：EGFR抗体西妥昔单抗可以作为结直肠癌维持治疗的优化方案（COIN-B研究）

2014-07-15

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

GCS 2014：西妥昔单抗不改善食管癌患者生存

2014-02-05

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）

2014-05-31

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Oncol：不推荐化疗+西妥昔单抗治疗晚期非小细胞肺癌

2014-02-23

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Cancer Chemother Pharmacol：西妥昔单抗安全用于肾损伤的癌症患者

2014-07-13

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

西妥昔单抗联合同步放化疗不改善NSCLC生存

2014-06-27

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

ASCO 2014：贝伐单抗+化疗方案和西妥昔单抗+化疗方案一线治疗转移性结直肠癌患者的疗效的研究（CALGB/SWOG 80405研究）

2015-03-04

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Oncol：FOLFOX方案加西妥昔单抗用于结直肠癌维持治疗方案（COIN-B研究）

2014-05-02

科室
- - 订阅+
  - 更多科室
工具
服务